We next mapped genes associated with factors and residual SUDs to the Drug-Gene-Interaction Database to identify druggable targets, with a particular emphasis on drugs with FDA approval for use in medication assisted treatment (MAT) of SUDs (Supplementary Table 18). For the factors, we used genes identified in at least three of the four gene-based methods. Given their lower power and the exploratory nature of these analyses, we used genes identified in any gene-based method for the residual SUD effects. We identified 118 druggable targets resulting in 1,024 FDA approved drug-gene interactions for Externalizing. Identified drugs included those used in MAT, including naltrexone, methadone hydrochloride, disulfiram, varenicline, baclofen, and acamprosate calcium. Genes identified for Behavioral Disinhibition and SUDs resulted in 96 and three druggable targets and 704 and 11 drug-gene interactions, respectively. Drugs used in MAT were also identified for each factor, but fewer types of drugs and at a lower rate compared with Externalizing. We found 16 and 28 druggable targets and 181 and 231 drug-gene interactions for residual PAU and PTU, respectively (Supplementary Table 19). We found that the
